Baxter Nicholas W 4
4 · Lexaria Bioscience Corp. · Filed Jul 25, 2023
Insider Transaction Report
Form 4
Baxter Nicholas W
Director
Transactions
- Award
Stock Options
2023-07-25+5,000→ 35,000 totalExercise: $0.87From: 2023-07-25Exp: 2028-07-25→ Common Shares (5,000 underlying)
Holdings
- 11,000
common shares
- 8,400
Stock Options
Exercise: $3.00From: 2021-09-01Exp: 2026-09-01→ Common Shares (1,900 underlying) - 11,800
Stock Options
Exercise: $3.39From: 2022-03-08Exp: 2027-03-08→ Common Shares (3,400 underlying) - 1,500
Stock Options
Exercise: $3.00From: 2021-04-26Exp: 2026-04-26→ Common Shares (1,500 underlying) - 6,500
Stock Options
Exercise: $3.00From: 2021-06-08Exp: 2026-06-08→ Common Shares (5,000 underlying) - 30,000
Stock Options
Exercise: $1.96From: 2022-10-12Exp: 2027-10-12→ Common Shares (18,200 underlying)
Footnotes (3)
- [F1]Repriced from $5.31 pursuant to shareholder approval received on May 9, 2023
- [F2]Repriced from $7.08 pursuant to shareholder approval received May 9, 2023
- [F3]Repriced from $6.23 pursuant to shareholder approval received May 9,2023